Infectious Disease Diagnostics Testing

Infectious Disease Diagnostics Testing Market Outlook

The global infectious disease diagnostics testing market was valued at approximately USD 21 billion in 2023 and is projected to reach around USD 38 billion by 2035, growing at a CAGR of about 7.4% during the forecast period. The rise in the prevalence of infectious diseases, coupled with increasing healthcare expenditure and advancements in diagnostic technologies, are significant factors driving the growth of this market. Moreover, the urgent need for rapid and accurate diagnostic tests, especially in the wake of global pandemics, has led to increased investment in research and development. The growing awareness about the importance of early diagnosis is further propelling this market, as timely interventions can significantly reduce mortality rates associated with infectious diseases.

Growth Factor of the Market

The growth of the infectious disease diagnostics testing market is significantly fueled by the rising incidence of infectious diseases globally. As urbanization and globalization continue to increase, the likelihood of disease transmission has escalated, necessitating efficient diagnostic solutions. Furthermore, advancements in biotechnology and molecular diagnostics have led to the development of more precise and rapid testing methods, thereby enhancing disease identification and management. The COVID-19 pandemic has also underscored the critical need for effective diagnostic testing, leading to substantial investments in this sector. Additionally, the growing emphasis on preventive healthcare and routine screening is driving demand for diagnostic tests across various populations, contributing to overall market growth.

Key Highlights of the Market

• Rapid growth driven by increased prevalence of infectious diseases and pandemics.
• Significant advancements in diagnostic technologies enhancing test accuracy and speed.
• Growing demand for point-of-care testing fueling market expansion.
• Government initiatives promoting early diagnosis and treatment.
• Collaboration between public and private sectors to improve diagnostics infrastructure.

By Product Type

Reagents & Kits:

The reagents and kits segment forms a cornerstone of the infectious disease diagnostics testing market, accounting for a significant share due to their fundamental role in the testing process. These products include various reagents that facilitate chemical reactions necessary for diagnostic tests, and kits that provide the necessary components for conducting tests. The increasing demand for rapid testing solutions, especially in critical situations like pandemics, has significantly boosted this segment. The advancement in reagent formulations and the introduction of user-friendly kits have made testing more accessible to healthcare providers. Moreover, the rising trend of home-based testing also propels the demand for these kits, making them an essential part of the market landscape.

Instruments:

The instruments segment covers a wide range of diagnostic equipment, including analyzers, spectrophotometers, and PCR machines. These instruments are critical for conducting various diagnostic tests accurately and efficiently. The increasing complexity of infections and the need for advanced diagnostic capabilities are leading to greater investments in sophisticated instruments. Furthermore, technological innovations such as automation and integration with IT systems are enhancing the functionality and efficiency of diagnostic instruments, catering to the growing demands of laboratories and hospitals. As laboratories strive for higher throughput and efficiency, the instruments segment expects substantial growth, driven by consistent technological advancements and increasing laboratory automation.

Services:

The services segment encompasses a range of offerings including testing services, maintenance, and support services for diagnostic equipment. With the proliferation of diagnostic testing facilities, the need for reliable and efficient service offerings has become paramount. Outsourcing diagnostic testing services to specialized laboratories is increasingly common, driven by the need for rapid, accurate results without the burden of equipment maintenance and management. The growth of telehealth services, particularly post-COVID-19, has also contributed to the expansion of this segment. This trend allows healthcare providers to offer diagnostic services remotely, further enhancing convenience and accessibility, and thus fostering the growth of the services market within the diagnostics sector.

By Technology

Polymerase Chain Reaction:

Polymerase Chain Reaction (PCR) technology is one of the most widely used and recognized methodologies in the infectious disease diagnostics testing market. PCR allows for the amplification of specific DNA sequences, making it highly sensitive and capable of detecting even minimal amounts of pathogens in a sample. The increasing prevalence of infectious diseases and the emphasis on early diagnosis are propelling the adoption of PCR testing across laboratories. The technology's versatility in applications, including the detection of viral, bacterial, and parasitic infections, further enhances its market significance. Additionally, advancements in real-time PCR technology are providing faster results, making it an essential tool in clinical diagnostics and research settings.

Immunoassays:

Immunoassays represent a critical technology segment in the infectious disease diagnostics testing market, employing antigen-antibody interactions to identify the presence of pathogens or their antibodies. This technology is particularly beneficial for diseases where rapid diagnosis is essential, such as HIV and hepatitis. The versatility and ease of use of immunoassays contribute significantly to their widespread adoption in laboratories and healthcare settings. Moreover, the introduction of more sensitive and specific immunoassay kits is improving diagnostic accuracy and reducing the incidence of false positives and negatives. As the demand for point-of-care testing continues to grow, immunoassays are anticipated to play an increasingly vital role in the market.

Molecular Diagnostics:

Molecular diagnostics are revolutionizing the infectious disease diagnostics testing landscape by providing a deeper understanding of the pathogens involved and enabling more targeted treatment approaches. This technology focuses on analyzing genetic material (DNA or RNA) from pathogens, allowing for precise identification and characterization of infectious agents. The growing trend towards personalized medicine is driving interest in molecular diagnostics, as it enables healthcare providers to tailor treatments based on specific pathogen characteristics. Additionally, the increasing prevalence of antimicrobial resistance is heightening the need for accurate and rapid molecular diagnostics, positioning this sub-segment for substantial growth in the coming years.

Isothermal Nucleic Acid Amplification Technology:

Isothermal Nucleic Acid Amplification Technology (INAAT) is gaining traction as an alternative to traditional PCR-based methods due to its ability to amplify nucleic acids at a constant temperature, eliminating the need for complex thermal cycling equipment. This technology is particularly valuable in resource-limited settings where access to laboratory equipment is restricted. The simplicity and rapid turnaround time of INAAT make it an attractive option for point-of-care diagnostics, especially in the context of emerging infectious diseases. As the demand for quick and accessible testing solutions rises, INAAT is expected to contribute significantly to the growth of the infectious disease diagnostics testing market.

Others:

The 'Others' segment encompasses various diagnostic technologies that do not fall under the primary categories mentioned previously. This includes emerging technologies such as CRISPR-based diagnostics and next-generation sequencing, which are showing promise in identifying infectious agents with high specificity and sensitivity. The growth of innovative diagnostic solutions is driven by ongoing research and development efforts aimed at combating infectious diseases through novel approaches. Furthermore, the shift toward decentralized testing and home-based diagnostics is fostering the exploration and adoption of alternative technologies. As the landscape of infectious disease diagnostics continues to evolve, these innovative technologies are expected to carve out a significant niche in the overall market.

By Disease Indication

HIV:

The HIV diagnostics segment is a critical component of the infectious disease diagnostics testing market, driven by the urgent need for early detection and effective management of the disease. Accurate and timely testing is essential for initiating antiretroviral therapy (ART) and preventing transmission. Innovative testing methods, including rapid tests and self-testing kits, are enhancing access to HIV diagnostics, particularly in underserved populations. The increasing awareness and education regarding HIV/AIDS, along with government initiatives to improve testing rates, are further propelling this segment's growth. As the global fight against HIV continues, advancements in diagnostic technologies are expected to play a key role in reducing infection rates and improving patient outcomes.

Hepatitis:

The hepatitis diagnostics segment remains vital within the infectious disease diagnostics testing market, owing to the significant global burden of hepatitis infections. With various types of hepatitis viruses (A, B, C, D, and E) affecting millions worldwide, accurate and timely diagnostics are essential for effective treatment and management. The rising incidence of chronic hepatitis, particularly hepatitis B and C, is driving demand for reliable diagnostic tests. Advancements in serological and molecular testing methods have improved diagnostic accuracy and speed, facilitating early diagnosis and treatment initiation. As awareness of hepatitis's long-term health implications grows, so too will the need for effective diagnostic testing solutions, enhancing this segment's market relevance.

Influenza:

The influenza diagnostics segment is critical in the context of seasonal epidemics and potential pandemics, necessitating rapid and accurate testing capabilities. With the frequent mutation of influenza viruses, timely identification of the circulating strains is crucial for public health responses. Diagnostic technologies such as rapid antigen tests and molecular assays are widely used to facilitate swift diagnosis, allowing for timely antiviral treatments. The increasing focus on influenza surveillance and vaccine efficacy monitoring further boosts the demand for effective diagnostic tests. As global health agencies continue to prioritize influenza preparedness, the diagnostics segment for influenza is expected to witness steady growth.

Tuberculosis:

Tuberculosis (TB) diagnostics represent a significant focus area in the infectious disease diagnostics testing market, particularly in regions with high TB prevalence. Accurate and timely diagnosis is essential for effective treatment and controlling transmission. The introduction of molecular diagnostics, such as GeneXpert, has revolutionized TB testing by providing rapid and accurate results. Additionally, the growing emphasis on latent TB infection screening is driving demand for various diagnostic solutions. As global health initiatives work towards eradicating TB, the diagnostics segment dedicated to this disease is anticipated to experience substantial growth, supported by advancements in testing technologies and increased awareness about TB's public health impact.

COVID-19:

The COVID-19 diagnostics segment has surged dramatically in response to the global pandemic, highlighting the critical importance of rapid and accurate testing. Various diagnostic methods, including PCR, rapid antigen tests, and serological assays, have been developed to identify active infections and past exposures. The unprecedented demand for COVID-19 testing has accelerated innovation in the diagnostics field, leading to the rapid development and deployment of new testing technologies. As countries move towards managing COVID-19 as an endemic disease, ongoing testing and monitoring will remain crucial, ensuring that the COVID-19 diagnostics segment continues to play a vital role in public health strategy.

Others:

The 'Others' segment under disease indication encompasses a variety of infectious diseases that require diagnostic testing, such as malaria, dengue fever, and respiratory syncytial virus (RSV). These diseases, while perhaps less pervasive than HIV or COVID-19, still pose significant health challenges globally. The diagnostics methods for these diseases include serological tests, rapid diagnostic tests, and molecular assays, which are essential for timely diagnosis and treatment. The increasing global travel and migration patterns contribute to the spread of these infectious diseases, underlining the need for effective diagnostics. As awareness grows and new testing technologies emerge, this segment is poised for growth within the infectious disease diagnostics testing market.

By End User

Hospitals:

Hospitals are a primary end user in the infectious disease diagnostics testing market, as they require accurate and rapid testing to diagnose and treat patients effectively. The integration of sophisticated diagnostic technologies within hospital laboratories enhances the capacity for timely testing, critical for managing infectious disease outbreaks. With increasing patient volumes and the rising prevalence of infectious diseases, hospitals are investing in advanced diagnostic equipment and training for healthcare professionals. The trend toward personalized medicine and targeted therapies further underscores the importance of reliable diagnostics in hospital settings. As hospitals strive for improved patient outcomes, the demand for diverse diagnostic testing solutions is expected to grow, solidifying their position as a key end user in the market.

Diagnostic Laboratories:

Diagnostic laboratories serve as crucial players in the infectious disease diagnostics testing market, providing specialized testing capabilities for a wide range of infectious diseases. These laboratories often operate independently or as part of larger healthcare networks, delivering rapid and accurate test results to healthcare providers. The growing demand for outsourced testing services, particularly during disease outbreaks, bolsters the importance of diagnostic laboratories. Advances in automation and technology integration are enhancing the efficiency and accuracy of laboratory testing, allowing for higher throughput and better resource management. As healthcare systems continue to prioritize timely diagnostics, diagnostic laboratories are expected to experience significant growth in this segment.

Research Institutes:

Research institutes play a pivotal role in advancing the infectious disease diagnostics testing market by developing new testing methodologies and exploring emerging infectious diseases. These institutes are often at the forefront of innovation, conducting studies that lead to the discovery of novel diagnostic technologies and applications. The collaboration between research institutes and industry stakeholders is crucial for translating research findings into practical diagnostic solutions. Furthermore, the increasing focus on global health security and the need for preparedness against potential outbreaks are driving funding towards research initiatives. As research activities expand and new pathogens emerge, the contribution of research institutes to the diagnostics market is likely to grow, fostering innovation and enhancing testing capabilities.

Others:

The 'Others' segment for end users encompasses various organizations and entities involved in infectious disease diagnostics testing, such as public health agencies and academic institutions. These entities may engage in testing for surveillance, outbreak response, and research purposes. Public health agencies play a crucial role in monitoring infectious disease trends and ensuring the availability of diagnostic resources, particularly during public health emergencies. Academic institutions often collaborate with industry partners to advance diagnostic research and training for future healthcare professionals. The diverse activities and missions of these organizations contribute to the overall growth and evolution of the infectious disease diagnostics testing market as they strive to improve health outcomes through effective diagnostics.

By Region

The North American region dominates the infectious disease diagnostics testing market, contributing over 40% of the global market share in 2023. The prevalence of infectious diseases, coupled with significant healthcare expenditure and advanced healthcare infrastructure, underscores the region's leading position. The United States, in particular, plays a crucial role, driven by extensive research and development initiatives and a strong emphasis on innovative diagnostic solutions. The market in North America is projected to grow at a CAGR of 6.9% from 2025 to 2035, fueled by ongoing technological advancements and increasing public awareness regarding infectious disease management.

In contrast, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, with a CAGR of approximately 8.5%. This rapid growth can be attributed to the rising incidence of infectious diseases, expanding healthcare infrastructure, and increasing investments in diagnostic technologies. Countries like India and China are experiencing significant advancements in healthcare access and diagnostic capabilities, making them pivotal markets in this region. As healthcare systems continue to evolve and improve, the demand for effective infectious disease diagnostics is expected to surge considerably in Asia Pacific countries, contributing to the overall global market growth.

Opportunities

The infectious disease diagnostics testing market presents numerous opportunities, particularly in the realm of technological advancements and innovations. With the continuous progression of diagnostic technologies, there is a growing potential for the development of rapid and highly sensitive tests that can be deployed in various settings, including point-of-care testing. The advent of digital health technologies and telemedicine platforms offers new avenues for delivering diagnostic services, enhancing access for underserved populations. Collaborations between public health organizations, research institutions, and private companies are likely to lead to transformative solutions in diagnostics, improving the ability to respond to emerging infectious diseases and outbreaks effectively. Additionally, the expansion of diagnostic capabilities in developing regions represents a significant opportunity for the market to grow, ensuring that essential diagnostic services are available globally.

Moreover, the increasing emphasis on preventive healthcare and routine screenings for infectious diseases is paving the way for enhanced diagnostic testing. Governments and health organizations are prioritizing early detection strategies to mitigate the impact of infectious diseases on public health. This growing focus on preventive measures opens opportunities for the development of screening programs that integrate diagnostic testing into routine healthcare practices. The rise in global travel and trade further fuels the necessity for effective infectious disease surveillance and diagnostics, creating opportunities for diagnostic companies to expand their reach and provide valuable solutions to diverse markets. As the landscape of healthcare continues to evolve, the infectious disease diagnostics testing market is poised to capitalize on these opportunities for sustainable growth.

Threats

Despite the promising opportunities, the infectious disease diagnostics testing market faces several threats that may hinder its growth. One of the key challenges is the rapid emergence of new infectious diseases and the evolving nature of existing pathogens, which can complicate the development of accurate and timely diagnostic tests. The increasing prevalence of antimicrobial resistance presents another significant concern, as it necessitates constant adaptation of diagnostic methodologies to ensure effective treatment options are available. Moreover, the stringent regulatory requirements for diagnostic tests can result in prolonged approval timelines, potentially delaying the delivery of innovative solutions to the market. These factors create an ever-changing landscape in the diagnostics market, necessitating agility and adaptability from industry players to remain competitive.

Another threat to the market is the potential for market saturation, particularly in regions where access to diagnostic testing has improved significantly. As competition intensifies, companies may face pressure on pricing and profitability, which can impact their ability to invest in research and development. Additionally, the reliance on third-party laboratories for testing can pose operational challenges, including variability in testing standards and quality control. The increasing trend towards decentralized testing solutions, while beneficial in many respects, may also lead to inconsistencies in testing outcomes across different settings. Addressing these threats will require strategic planning and innovation from market participants to navigate the complexities of the infectious disease diagnostics landscape effectively.

Competitor Outlook

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Thermo Fisher Scientific
• Becton, Dickinson and Company
• Quidel Corporation
• bioMérieux SA
• Cepheid, Inc.
• Hologic, Inc.
• Danaher Corporation
• PerkinElmer, Inc.
• GenMark Diagnostics, Inc.
• Ortho Clinical Diagnostics
• Abbott Diagnostics
• Agilent Technologies, Inc.

The competitive landscape of the infectious disease diagnostics testing market is characterized by a diverse array of players, including established market leaders and innovative startups. Major companies such as Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers dominate the market, leveraging their extensive product portfolios, advanced technologies, and strong brand recognition. These players continuously invest in research and development to introduce innovative diagnostic solutions that cater to the evolving healthcare landscape. Collaborations and partnerships between these companies and research institutions are common, aiming to enhance diagnostic capabilities and address emerging infectious disease challenges effectively. The competitive dynamics within this market encourage ongoing innovation and improvement, ensuring that players remain responsive to changing market demands.

Roche Diagnostics stands out as a pioneer in the field, offering a comprehensive range of diagnostic products and solutions for infectious diseases. With a strong focus on molecular diagnostics, Roche has developed cutting-edge testing methodologies that facilitate rapid and accurate results. Their robust research and development pipeline, coupled with strategic acquisitions, positions Roche as a leader in the diagnostics market. Abbott Laboratories also plays a significant role, recognized for its innovative diagnostic technologies, including rapid tests and molecular assays. Their commitment to enhancing patient care through advanced diagnostics has solidified their place among the top competitors in the market.

Siemens Healthineers brings a wealth of experience and expertise in medical diagnostics, offering an extensive portfolio that includes advanced imaging solutions and laboratory diagnostics. Their focus on integrating digital health solutions with traditional diagnostics enhances their value proposition, allowing healthcare providers to make informed decisions based on real-time data. Additionally, companies like Thermo Fisher Scientific and Becton, Dickinson and Company are actively investing in the expansion of their infectious disease diagnostics offerings to strengthen their market positions. The overall competitive landscape is dynamic, with industry players constantly working to innovate and adapt to the changing needs of healthcare providers and patients alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Cepheid, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 PerkinElmer, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Roche Diagnostics
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Abbott Diagnostics
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Quidel Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Danaher Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Siemens Healthineers
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 bioMérieux SA
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Thermo Fisher Scientific
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 GenMark Diagnostics, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Agilent Technologies, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Ortho Clinical Diagnostics
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Becton, Dickinson and Company
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Infectious Disease Diagnostics Testing Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Laboratories
    • 6.1.3 Research Institutes
    • 6.1.4 Others
  • 6.2 Infectious Disease Diagnostics Testing Market, By Technology
    • 6.2.1 Polymerase Chain Reaction
    • 6.2.2 Immunoassays
    • 6.2.3 Molecular Diagnostics
    • 6.2.4 Isothermal Nucleic Acid Amplification Technology
    • 6.2.5 Others
  • 6.3 Infectious Disease Diagnostics Testing Market, By Product Type
    • 6.3.1 Reagents & Kits
    • 6.3.2 Instruments
    • 6.3.3 Services

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Infectious Disease Diagnostics Testing Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Infectious Disease Diagnostics Testing market is categorized based on

By Product Type

• Reagents & Kits
• Instruments
• Services

By Technology

• Polymerase Chain Reaction
• Immunoassays
• Molecular Diagnostics
• Isothermal Nucleic Acid Amplification Technology
• Others

By End User

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Thermo Fisher Scientific
• Becton, Dickinson and Company
• Quidel Corporation
• bioMérieux SA
• Cepheid, Inc.
• Hologic, Inc.
• Danaher Corporation
• PerkinElmer, Inc.
• GenMark Diagnostics, Inc.
• Ortho Clinical Diagnostics
• Abbott Diagnostics
• Agilent Technologies, Inc.